Log In
Print
BCIQ
Print
Print this Print this
 

muparfostat (PI-88)

  Manage Alerts
Collapse Summary General Information
Company Progen Pharmaceuticals Ltd.
DescriptionSulfated mannopentaose phosphate anti-angiogenic agent that inhibits VEGF, FGF and heparanase activity
Molecular Target Vascular endothelial growth factor (VEGF) ; Fibroblast growth factor (FGF)
Mechanism of ActionAngiogenesis inhibitor; Vascular endothelial growth factor (VEGF) inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase III
Standard IndicationLiver cancer
Indication DetailsAdjuvant treatment of hepatitis virus-related hepatocellular carcinoma (HCC) after surgical resection; Treat hepatocellular carcinoma (HCC) following primary tumor resection; Treat primary liver cancer
Regulatory Designation

U.S. - Orphan Drug (Adjuvant treatment of hepatitis virus-related hepatocellular carcinoma (HCC) after surgical resection);
EU - Orphan Drug (Adjuvant treatment of hepatitis virus-related hepatocellular carcinoma (HCC) after surgical resection)

Partner

Medigen Biotechnology Corp.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today